Logo     Print Page  Close Window


News Release


Fibrocell Announces Board Member Christine St.Clare Honored by National Association of Corporate Directors

- Annual NACD Directorship 100 List Recognizes the Most Influential Corporate Governance Experts -

EXTON, Pa., April 03, 2019 (GLOBE NEWSWIRE) -- Fibrocell Science, Inc. (Nasdaq: FCSC), a gene therapy company focused on transformational autologous cell-based therapies for skin and connective tissue diseases, today announced Christine St.Clare, a member of the Company’s Board of Directors and Audit Committee Chair, has been recognized by the National Association of Corporate Directors (NACD) as an honoree of the 2019 NACD Directorship 100, a list of the most influential leaders in the boardroom and corporate governance community.

“NACD’s prestigious recognition of Ms. St.Clare is a testament to the leadership, insight and guidance that she has continued to provide to Fibrocell as a member of our Board and chair of the Audit Committee during the past six years,” said John Maslowski, President and Chief Executive Officer of Fibrocell. “We applaud the NACD for acknowledging Ms. St.Clare’s respected counsel and contributions that foster excellence in corporate governance, and we are proud to be working with her.”

The honorees represent a range of companies, including Adobe, Bank of America, Best Buy, CenturyLink, Cisco Systems, Citigroup, General Mills, Intel, Liberty Mutual Holding, Lockheed Martin, Northrop Grumman, Sysco, Target, The American Red Cross, and Verizon Communications. Honorees will be recognized during the NACD Directorship 100 black tie gala on June 26 in New York City. The complete list of the 2019 NACD Directorship 100 is available at https://www.nacdonline.org/Directorship100/2019honorees.cfm.

The 2019 NACD Directorship 100 recognizes leading corporate directors and governance advocates in several categories, including attorneys, audit and risk professionals, board advisors, compensation experts, crisis communications experts, governance advisors, investors, media, members of the plaintiffs’ bar, policy advisors, recruiters, and regulators and rulemakers.

Nominees are evaluated in four key categories: integrity, mature confidence, informed judgment, and high-performance standards. An independent selection committee reviews the nominees’ history of advancing board performance and leading corporate governance practices in accordance with established NACD principles. The principles are a framework that encourages excellence in areas, including risk oversight, corporate strategy, compensation, and transparency.

NACD honoree Christine St.Clare’s career spans 35-years with KPMG LLP, where she served a four-year term on the firm’s Board of Directors and chaired the Board’s Audit and Finance Committee. Currently, in addition to being a member of Fibrocell’s Board of Directors and serving as chair of its Audit Committee, Ms. St.Clare serves on the Board of Directors of AquaBounty Technologies, Inc., and as the chair of its Audit Committee. Furthermore, she is a member of the Board of Directors of Tilray, Inc. and serves as chair of its Audit Committee and a member of the Nominating and Governance Committee. She served on the Board of Directors of Polymer Group, Inc. and as the chair of its Audit Committee until the company was sold in October 2015. Ms. St.Clare recently served on advisory boards of Houlihan Lokey, a midsize global, advisory-focused investment bank, Women Corporate Directors, and Emory University’s Goizueta Business School. Ms. St.Clare earned a B.S. in Accounting from California State University at Long Beach.

To learn more about the NACD Directorship 100, to view past honorees, and to register to attend the gala, visit www.NACDonline.org/D100

About Fibrocell  

Fibrocell is an autologous cell and gene therapy company translating personalized biologics into medical breakthroughs for diseases affecting the skin and connective tissue. Fibrocell's most advanced product candidate, FCX-007, is the subject of a Phase 1/2 clinical trial for the treatment of RDEB. Fibrocell is also developing FCX-013 for the treatment of moderate to severe localized scleroderma, and is currently enrolling the Phase 1 portion of a Phase 1/2 clinical trial.  Fibrocell's gene therapy portfolio is being developed in collaboration with Intrexon Corporation (Nasdaq: XON), a leader in synthetic biology.  For more information, visit www.fibrocell.com or follow Fibrocell on Twitter at @Fibrocell.

Trademarks  

Fibrocell®, the Fibrocell logo, and Fibrocell Science® are trademarks of Fibrocell Science, Inc. and/or its affiliates.  All other names may be trademarks of their respective owners.

About NACD

The National Association of Corporate Directors (NACD) empowers more than 20,000 directors to lead with confidence in the boardroom. As the recognized authority on leading boardroom practices, NACD helps boards strengthen investor trust and public confidence by ensuring that today’s directors are well prepared for tomorrow’s challenges. World-class boards join NACD to elevate performance, gain foresight, and instill confidence. Fostering collaboration among directors, investors, and corporate governance stakeholders, NACD has been setting the standard for responsible board leadership for 40 years. To learn more about NACD, visit www.NACDonline.org.

Fibrocell Media Contact:
Karen Casey
484.713.6133
kcasey@fibrocell.com

NACD Media Contact:
Susan Oliver
703.216.4078
susanboliver@gmail.com

Fibrocell.jpg

Fibrocell Science Inc.